We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
Read MoreHide Full Article
Key Takeaways
Stryker completed the first hip arthroscopy using SportSuite Vision on Apple Vision Pro at Duke Health.
SYK's app is the first FDA-authorized surgical application for intraoperative use with Apple Vision Pro.
Stryker's SportSuite Vision could support a more connected digital operating room in Sports Medicine.
Stryker (SYK - Free Report) recently announced the successful completion of the first hip arthroscopy procedure using its SportSuite Vision application on Apple Vision Pro at Duke Health. The milestone follows the FDA's De Novo authorization for the application in July, making it the first surgical application approved for intraoperative use with Apple's mixed reality headset.
From an investor's perspective, the development reinforces Stryker's push to strengthen its digital surgery portfolio and expand innovation across its Sports Medicine business. Although the launch is unlikely to materially affect near-term revenue, it could enhance the company's competitive position, support wider adoption of its surgical ecosystem and create long-term growth opportunities as hospitals increasingly embrace advanced operating room technologies.
Likely Trend of SYK Stock Following the News
Following the announcement, shares of SYK traded flat on Wednesday. Year to date, shares of the company have lost 11.1% compared with the industry’s 17% decline. However, the S&P 500 has risen 10.9% in the same timeframe.
In the long run, SportSuite Vision could strengthen Stryker's competitive moat by expanding its digital surgery ecosystem and making its Sports Medicine portfolio more integral to hospital workflows. As the first FDA-authorized intraoperative application for Apple Vision Pro, the platform gives Stryker an early-mover advantage in spatial computing, which could drive greater adoption at academic medical centers and high-volume orthopedic hospitals. Over time, this ecosystem approach may encourage repeat software and hardware purchases, deepen customer loyalty and support sustained growth across the company's surgical technologies business.
SYK currently has a market capitalization of $121.8 billion.
Image Source: Zacks Investment Research
Details of the News
Following the FDA's De Novo authorization on July 17, SportSuite Vision became the first application cleared for intraoperative use with Apple Vision Pro, establishing a new regulatory benchmark for spatial computing in the operating room. The first live use of the technology took place during a hip arthroscopy at Duke Health, where orthopedic surgeon Chad Mather III performed the procedure, demonstrating the platform's transition from regulatory clearance to real-world clinical adoption at a nationally recognized academic medical center.
SportSuite Vision is designed for femoroacetabular impingement and labral repair hip arthroscopy procedures, combining arthroscopic video, HipCheck, HipMap FAI Analysis and CT imaging within a customizable spatial computing environment. The software allows surgeons to view these digital tools alongside the physical operating room through a video see-through augmented reality headset, while operating room staff continue using traditional monitors. According to Stryker, this integrated approach represents another step toward building a more connected digital operating room across its Sports Medicine franchise.
Benefits for Surgeons
The new platform is designed to make hip arthroscopy more intuitive by keeping critical clinical information within the surgeon's line of sight throughout the procedure. Instead of repeatedly looking toward multiple monitors positioned around the operating room, surgeons can arrange key data based on their preferred workflow and access it within the sterile field. This setup can create a more comfortable and ergonomic operating environment, reduce unnecessary head movement and help streamline procedures by keeping essential information readily visible during surgery.
Industry Prospects Favoring the Market
Going by the data provided by Research and Markets, the digital surgery technologies market size is expected to see exponential growth in the next few years. The market was valued at $1.48 billion in 2025 and is likely to reach beyond $5.36 billion by 2030 at a CAGR of 28.3%.
Growth in the forecast period can be attributed to the expansion of AI and big data in surgical workflows, growth of extended reality applications in surgery, increased adoption of software-based surgical navigation, development of advanced robotics control software and installation and maintenance services for digital surgical systems.
Other News
Recently, SYK announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker’s shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care.
Per Stryker management, ZuriMED’s technology addresses an important unmet need for shoulder care.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
View the Zacks #1 Rank List
Image: Bigstock
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
Key Takeaways
Stryker (SYK - Free Report) recently announced the successful completion of the first hip arthroscopy procedure using its SportSuite Vision application on Apple Vision Pro at Duke Health. The milestone follows the FDA's De Novo authorization for the application in July, making it the first surgical application approved for intraoperative use with Apple's mixed reality headset.
From an investor's perspective, the development reinforces Stryker's push to strengthen its digital surgery portfolio and expand innovation across its Sports Medicine business. Although the launch is unlikely to materially affect near-term revenue, it could enhance the company's competitive position, support wider adoption of its surgical ecosystem and create long-term growth opportunities as hospitals increasingly embrace advanced operating room technologies.
Likely Trend of SYK Stock Following the News
Following the announcement, shares of SYK traded flat on Wednesday. Year to date, shares of the company have lost 11.1% compared with the industry’s 17% decline. However, the S&P 500 has risen 10.9% in the same timeframe.
In the long run, SportSuite Vision could strengthen Stryker's competitive moat by expanding its digital surgery ecosystem and making its Sports Medicine portfolio more integral to hospital workflows. As the first FDA-authorized intraoperative application for Apple Vision Pro, the platform gives Stryker an early-mover advantage in spatial computing, which could drive greater adoption at academic medical centers and high-volume orthopedic hospitals. Over time, this ecosystem approach may encourage repeat software and hardware purchases, deepen customer loyalty and support sustained growth across the company's surgical technologies business.
SYK currently has a market capitalization of $121.8 billion.
Image Source: Zacks Investment Research
Details of the News
Following the FDA's De Novo authorization on July 17, SportSuite Vision became the first application cleared for intraoperative use with Apple Vision Pro, establishing a new regulatory benchmark for spatial computing in the operating room. The first live use of the technology took place during a hip arthroscopy at Duke Health, where orthopedic surgeon Chad Mather III performed the procedure, demonstrating the platform's transition from regulatory clearance to real-world clinical adoption at a nationally recognized academic medical center.
SportSuite Vision is designed for femoroacetabular impingement and labral repair hip arthroscopy procedures, combining arthroscopic video, HipCheck, HipMap FAI Analysis and CT imaging within a customizable spatial computing environment. The software allows surgeons to view these digital tools alongside the physical operating room through a video see-through augmented reality headset, while operating room staff continue using traditional monitors. According to Stryker, this integrated approach represents another step toward building a more connected digital operating room across its Sports Medicine franchise.
Benefits for Surgeons
The new platform is designed to make hip arthroscopy more intuitive by keeping critical clinical information within the surgeon's line of sight throughout the procedure. Instead of repeatedly looking toward multiple monitors positioned around the operating room, surgeons can arrange key data based on their preferred workflow and access it within the sterile field. This setup can create a more comfortable and ergonomic operating environment, reduce unnecessary head movement and help streamline procedures by keeping essential information readily visible during surgery.
Industry Prospects Favoring the Market
Going by the data provided by Research and Markets, the digital surgery technologies market size is expected to see exponential growth in the next few years. The market was valued at $1.48 billion in 2025 and is likely to reach beyond $5.36 billion by 2030 at a CAGR of 28.3%.
Growth in the forecast period can be attributed to the expansion of AI and big data in surgical workflows, growth of extended reality applications in surgery, increased adoption of software-based surgical navigation, development of advanced robotics control software and installation and maintenance services for digital surgical systems.
Other News
Recently, SYK announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker’s shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care.
Per Stryker management, ZuriMED’s technology addresses an important unmet need for shoulder care.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
SYK’s Zacks Rank & Key Picks
Currently, SYK has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.